Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Dermatological, Oncological, and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MC1R drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | MC1R Promise-ORF / Lentivirus Full-length ORF for stable cell lines in HEK293 or melanoma backgrounds. Essential for GPCR conformation & native glycosylation. |
View MC1R Products |
| Antigen | MC1R Full-Length Membrane Protein Preparation (VLP-free) & Mutant Peptides Lentivirus-mediated expression. Sequence Verified. Endotoxin <1EU/ug. Multiple variants available. |
View MC1R Products |
| Benchmark Ab | Anti-MC1R Reference Antibody (Biosimilar Control) Recombinant positive control for binding and functional assays. Sequence Verified. |
View MC1R Products |
| Validator | MC1R siRNA Set For knockdown verification and specificity controls. Endotoxin controlled. |
View MC1R Products |
| Related Target A | MC4R Selectivity counter-screening for melanocortin receptor family; metabolic safety target. |
View MC4R Products |
| Related Target B | MC2R (ACTH Receptor) Critical off-target for selectivity screening; high homology member. |
View MC2R Products |
| Related Target C | TYR (Tyrosinase) Downstream effector of melanin synthesis pathway. |
View TYR Products |
| Related Target D | POMC Endogenous ligand precursor, pathway node for mechanism studies. |
View POMC Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation (7-TM GPCR) | Lentivirus Premade Particles for stable cell line generation in HEK293. Ensures native folding, glycosylation, and signaling competence for cAMP assays. Theoretical MW verified. |
| Melanocortin Receptor Selectivity (MC1R vs MC2R/4R/5R) | Human MC2R/MC3R/MC4R/MC5R ortholog proteins available for cross-reactivity panels. Sequence verified, >95% purity. |
| Lack of Reliable Controls | Recombinant positive control antibodies included for benchmarking. |
| False Positives in Cell Assays | Validated siRNA included for rigorous specificity checks. |
| Internalization Kinetics for ADC & Radiopharmaceuticals | High-expression stable cell lines enabling quantitative internalization assays with pH-sensitive dyes; live-cell imaging compatible. |
| Functional cAMP Pathway Validation | Cell lines with endogenous Gs coupling preserved for second messenger assays. |
Live MC1R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MC1R therapeutics is intensifying, with major players expanding focus from synthetic peptides (e.g., afamelanotide) to novel small molecules, targeted radiopharmaceuticals, and antibody-drug conjugates. As first-generation therapies for rare porphyrias (e.g., erythropoietic protoporphyria) reach the clinic, the next wave of R&D is targeting broader dermatological indications like vitiligo, melanoma prevention, and systemic inflammatory disorders. Selective modulation to avoid off-target effects on the hypothalamic-pituitary-adrenal (HPA) axis is a key focus.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Agonists | Clinuvel Pharmaceuticals | EPP, Vitiligo, Photoprotection | Receptor Binding / cAMP Accumulation (Need full-length native conformation, lentivirus-stable lines) |
| Small Molecules | Various Biotechs, Pre-clinical | Inflammation, Pigmentation Disorders | Selectivity Assay vs MC2R/MC4R (Need homolog family proteins >95% purity) |
| Antibodies | Academic / Early Phase | Melanoma Targeting | Binding Assays (Need stable expressing cells with native glycosylation) |
| Radiopharmaceuticals | Academic Consortia, Emerging Biotech | Melanoma Imaging/Therapy | Cell Surface Expression Quantification (Need high-expression stable lines) |
| ADC | Early Pipeline (Pre-clinical) | Metastatic Melanoma | Internalization Efficiency & Recycling Rate (Need live-cell imaging compatible lentivirus lines) |
Key MC1R Genetic Variants and Assay Implications
MC1R is highly polymorphic; certain variants are associated with altered receptor function and disease risk. The following key mutations (from UniProt and dbSNP) have important implications for drug development and assay design:
| Variant | Effect | Clinical / Biological Relevance | Assay Consideration |
|---|---|---|---|
| R151C (rs7481) | Partial loss-of-function; correlated with fair hair and light skin | Reduced melanogenesis; increased melanoma risk | Assays must differentiate partial vs full agonism; use variant-expressing cell lines for selectivity |
| D294H (in CMM5) | Moderate decrease in coupling to cAMP pathway; reduced cell surface expression | Associated with melanoma susceptibility | Requires high-sensitivity cAMP assays; cell surface quantification critical |
| D294H homozygosity (in CMM5) | Complete absence of functional coupling to cAMP pathway; reduced cell surface | Severe loss-of-function; elevated melanoma risk | Functional assays (cAMP, β-arrestin) essential; use isogenic cell panels |
These variants underscore the need for assay systems that can differentiate wild-type from common polymorphic forms, especially for precision medicine approaches.